Objectives: Elizabethkingia meningoseptica has been known to infect the immunocompromised, preterm children, those exposed to antibiotics in critical care units, and those with comorbidities. Multidrug resistance seen in E. meningoseptica makes it daunting to choose the right antimicrobial agents for treating infections caused by this organism. The present study was undertaken to establish the incidence of E. meningoseptica infections, to investigate the clinical features and risk factors associated with these infections, and to study the antimicrobial susceptibility pattern of E. meningoseptica isolates over 2 years.

Methods: Medical records of the patient positive for E. meningoseptica from January 2015 to December 2016 were studied retrospectively. The demographic and clinical data of the patients and the antibiotic sensitivity patterns were collected and analyzed.

Results: E. meningoseptica was isolated from 13 patients. The mean age was 71.09 years with males being more frequently infected (81.8%). Maximum isolates were from blood (38.5%) with sepsis being the final diagnosis in 53.8% of the patients, followed by respiratory tract infection (46.1%). Two pediatric patients presented with both sepsis and meningitis. Nine patients (69.2%) recovered, and death occurred in four patients (30.8%). Susceptibility testing revealed 100% in vitro resistance to most of the antibiotics such as amikacin, aztreonam, cefepime, ceftazidime, colistin, gentamicin, meropenem, and polymyxin B which are used to treat Gram-negative bacterial infections. The isolates were most susceptible to minocycline and piperacillin.

Conclusion: E. meningoseptica is an emerging pathogen and is being isolated more frequently now. An expeditious and prompt institution of appropriate therapy is essential because of its inherent resistance to many antimicrobial agents commonly used to treat infections caused by Gram-negative bacteria.

Keywords: Comorbidities, Elizabethkingia meningoseptica, Immunocompromised, Multidrug resistance, Hospital.

Author Biographies

Varun Venkatesh, Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India.
Ashwini Hegde, Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India.

Associate Professor of Microbiology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education

Radhakrishna M, Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India.

Associate Professor and Consultant Microbiologist

Department of Microbiology


1. Bloch KC, Nadarajah R, Jacobs R. Chryseobacterium meningosepticum: An emerging pathogen among immunocompromised adults. Medicine (Baltimore) 1997;76:30-41.
2. Henriques IS, Araújo S, Azevedo JS, Alves MS, Chouchani C, Pereira A, et al. Prevalence and diversity of carbapenem-resistant bacteria in untreated drinking water in Portugal. Microb Drug Resist 2012;18:531 7.
3. Lin PY, Chen HL, Huang CT, Su LH, Chiu CH. Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia. Int J Antimicrob Agents 2010;36:436-40.
4. Jiang X, Wang D, Wang Y, Yan H, Shi L, Zhou L. Occurrence of antimicrobial resistance genes sul and dfrA12 in hospital environmental isolates of Elizabethkingia meningoseptica. World J Microbiol Biotechnol 2012;28:3097-102.
5. Ceyhan M, Yildirim I, Tekeli A, Yurdakok M, Us E, Altun B. A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients. Am J Infect Control 2008;36:453-7.
6. Hoque SN, Graham J, Kaufmann ME, Tabaqchali S. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J Hosp Infect 2001;47:188-92.
7. Ghafur A, Vidyalakshmi PR, Priyadarshini K, Easow JM, Raj R, Raja T. Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: The first case series from India. South Asian J Cancer 2013;2:211 5.
8. Tak V, Mathur P, Varghese P, Misra MC. Elizabethkingia meningoseptica: An emerging pathogen causing meningitis in a hospitalized adult trauma patient. Indian J Med Microbiol 2013;31:293-5.
9. Ratnamani MS, Rao R. Elizabethkingia meningoseptica: Emerging nosocomial pathogen in bedside hemodialysis patients. Indian J Crit Care Med 2013;17:304-7.
10. Gonzalez LJ, Vila AJ. Carbapenem resistance in Elizabethkingia meningoseptica is mediated by metallo-β-lactamase BlaB. Antimicrob Agents Chemother 2012;4:1686-92.
11. Hsu MS, Liao CH, Huang YT, Liu CY, Yang CJ, Kao KL, et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical centre in Taiwan, 1999–2006. Eur J ClinMicrobiol Infect Dis 2011;30:1971-8.
12. Pereira GH, Garcia DO, Abboud CS, Barbosa VL, Silva PS. Nosocomial infections caused by Elizabethkingia meningoseptica: An emergent pathogen. Braz J Infect Dis 2013;17:606-9.
13. Lin YT, Chiu CH, Chan YJ, Lin ML, Yu KW, Wang FD. Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan. Scand J Infect Dis 2009;41:628-34.
14. Chang YC, Lo HH, Hsieh HY, Chang SM. Identification and epidemiological relatedness of clinical Elizabethkingia meningoseptica isolates from central Taiwan. J Microbiol Immunol Infect 2014;47:318 23.
15. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J 2014;7:45-8.
16. Ceyhan M, Celik M. Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) infections in children. Int J Pediatr 2011;2011:215237.
17. Rastogi N, Mathur P, Bindra A, Goyal K, Sokhal N, Kumar S, et al. Infections due to Elizabethkingia meningoseptica in critically injures trauma patients: A seven-year study. J Hosp Infect 2016;92:30-2.
18. Lin PY, Chu C, Su LH, Huang CT, Chang WY, Chiu CH. Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningosepticum in nonneonatal patients. J Clin Microbiol 2004;7:3353-5.
19. Connell PP, Wickremasinghe S, Devi U, Waters MJ, Allen PJ. Self-induced Elizabethkingia meningoseptica endophthalmitis: A case report. J Med Case Rep 2011;5:303.
20. Hagiya H, Ogawa H, Takahashi Y, Hasegawa K, Iwamuro M, Otsuka F. A nephrostomy-associated urinary tract infection caused by Elizabethkingia meningoseptica. Intern Med 2015;54:3233-6.
21. Yang YS, Chun JW, Koh JW. Keratitis with Elizabethkingia meningoseptica occurring after contact lens wear: A case report. Korean J Ophthalmol 2013;27:133-6.
22. Jung SH, Lee B, Mirrakhimov AE, Hussain N. Septic shock caused by Elizabethkingia meningoseptica: A case report and review of the literature. BMJ Case Rep 2013;2013. pii: bcr2013009066.
23. du Moulin GC. Airway colonization by Flavobacterium in an intensive care unit. J Clin Microbiol 1979;10:155-60.
24. Nulens E, Bussels B, Bols A, Gordts B, Van Landuyt HW. Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device. Clin Microbiol Infect 2001;7:91-3.
25. Maraki S, Scoulica E, Manoura A, Papageorgiou N, Giannakopoulou C, Galanakis E. A Chryseobacterium meningosepticum colonization outbreak in a neonatal intensive care unit. Eur J Clin Microbiol Infect Dis 2009;28:1415-9.
26. Weaver KN, Jones RC, Albright R, Thomas Y, Zambrano CH, Costello M, et al. Acute emergence of Elizabethkingia meningoseptica infection among mechanically ventilated patients in a long-term acute care facility. Infect Control Hosp Epidemiol 2010;31:54-8.
27. Moore LS, Owens DS, Jepson A, Turton JF, Ashworth S, Donaldson H, et al. Waterborne Elizabethkingia meningoseptica in adult critical care. Emerg Infect Dis 2016;22:9-17.
116 Views | 202 Downloads
How to Cite
Venkatesh, V., A. Hegde, and R. M. “CLINICAL FEATURES AND ANTIMICROBIAL SUSCEPTIBILITIES OF ELIZABETHKINGIA MENINGOSEPTICA - AN EMERGING PATHOGEN FROM A TERTIARY CARE HOSPITAL IN MANGALORE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 11, Nov. 2018, pp. 110-3, doi:10.22159/ajpcr.2018.v11i11.27755.
Original Article(s)